In each case, FOXO fusion proteins result from translocations generating chimeric transcripts encoding the N-terminal region of the fusion partner (MLL for the leukemias, and either PAX3 or PAX7 for the rhabdomyosarcomas), and the C-terminal portion of the FOXO component. Here, KMT2A is linked to leukemia.